LAS VEGAS, Aug 10, 2000 (BUSINESS WIRE) -- ELAST Technologies, Inc.,
(OTC-BB:ESTG) www.elast.com announced this morning that Thomas F. Krucker, ELAST
President and CEO, will address the members of the Regional Investment Bankers
Association (RIBA) during its Chicago Capital Conference, August 17th through
19th, at the Ritz Carlton Four Seasons Hotel.
RIBA member James Lanni of First Midwest Securities is sponsoring ELAST
Technologies' participation at the Chicago Capital Conference and during the
three-day conference ELAST will be afforded the opportunity to make four
separate presentations to RIBA's members. RIBA is a national trade association
with offices in Charleston, South Carolina, and is comprised of approximately
135 NASD member broker/dealers. RIBA member firms managed or co-managed 706
offerings in the past 26 quarters and have raised approximately $6.6 billion in
new capital. RIBA's capital conferences are held four times annually and allow
its member firms to evaluate companies sponsored by other RIBA members.
ELAST Technologies, Inc., is a research and development enterprise whose primary
business is the development of the ELAST Device(TM). The U.S. allergy testing
market is estimated to be a $6 billion annual market (and is estimated to be a
$12 billion annual market worldwide).
The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed to
accurately diagnose allergies, as well as food and chemical sensitivities
immediately without any of the pain or expense associated with currently
employed testing methods. Existing allergy testing methods include the oral
challenge test as well as blood and skin prick testing. These methods require
the introduction of the potential allergen to the body. In contrast, the ELAST
Device(TM) is being designed to test for allergies and sensitivities
non-invasively through means of simple exposure, without the introduction into
the body of the potential allergen. The ELAST Device(TM) is based upon the
clinical observation that the normal flow of electricity in the human body is
altered when its immune system is exposed to a substance to which it is
sensitive or allergic. The non-invasive nature of the ELAST Device(TM) is
possible because the device measures the body's electrical response when it is
exposed to an allergen.
This news release contains forward-looking statements. Forward-looking
statements include statements concerning plans, objectives, goals, strategies,
future events or performance and underlying assumptions and other statements
that are other than statements of historical facts. These statements are subject
to uncertainties and risks including, but not limited to, product development
and consumer demand and acceptance, changes in technology, ability to raise
capital, the availability of appropriate acquisition candidates and/or business
partnerships, economic conditions, impact of competition and pricing, capacity
and supply constraints or difficulties, government regulation and other risks.
All such forward-looking statements whether written or oral, and whether made by
or on behalf of the Company are expressly qualified by these cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. In addition, the Company disclaims any obligation to
update any forward-looking statements to reflect events or circumstances after
the date hereof.
CONTACT: ELAST Technologies, Inc.
Michael Nanry
877/ELASTEC
877/352-7832 |
